<?xml version='1.0' encoding='utf-8'?>
<document id="25910235"><sentence text="Development and validation of LC-MS/MS assay for the determination of the prodrug Midodrine and its active metabolite Desglymidodrine in plasma of ascitic patients: Application to individualized therapy and comparative pharmacokinetics."><entity charOffset="82-91" id="DDI-PubMed.25910235.s1.e0" text="Midodrine" /><entity charOffset="118-133" id="DDI-PubMed.25910235.s1.e1" text="Desglymidodrine" /><pair ddi="false" e1="DDI-PubMed.25910235.s1.e0" e2="DDI-PubMed.25910235.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25910235.s1.e0" e2="DDI-PubMed.25910235.s1.e1" /></sentence><sentence text="Midodrine (MD) is a prodrug that is converted after oral administration to Desglymidodrine (DMD)"><entity charOffset="0-9" id="DDI-PubMed.25910235.s2.e0" text="Midodrine" /><entity charOffset="11-13" id="DDI-PubMed.25910235.s2.e1" text="MD" /><entity charOffset="75-90" id="DDI-PubMed.25910235.s2.e2" text="Desglymidodrine" /><entity charOffset="92-95" id="DDI-PubMed.25910235.s2.e3" text="DMD" /><entity charOffset="93-95" id="DDI-PubMed.25910235.s2.e4" text="MD" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e0" e2="DDI-PubMed.25910235.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e0" e2="DDI-PubMed.25910235.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e0" e2="DDI-PubMed.25910235.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e0" e2="DDI-PubMed.25910235.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e0" e2="DDI-PubMed.25910235.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e1" e2="DDI-PubMed.25910235.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e1" e2="DDI-PubMed.25910235.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e1" e2="DDI-PubMed.25910235.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e1" e2="DDI-PubMed.25910235.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e2" e2="DDI-PubMed.25910235.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e2" e2="DDI-PubMed.25910235.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e2" e2="DDI-PubMed.25910235.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e3" e2="DDI-PubMed.25910235.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25910235.s2.e3" e2="DDI-PubMed.25910235.s2.e4" /></sentence><sentence text=" In this study, an LC-MS/MS assay was developed and validated for investigation of the pharmacokinetics of MD and DMD in non azotemic patients with liver cirrhosis and tense ascites"><entity charOffset="107-108" id="DDI-PubMed.25910235.s3.e0" text="MD" /><entity charOffset="115-116" id="DDI-PubMed.25910235.s3.e1" text="MD" /><entity charOffset="114-115" id="DDI-PubMed.25910235.s3.e2" text="DMD" /><pair ddi="false" e1="DDI-PubMed.25910235.s3.e0" e2="DDI-PubMed.25910235.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25910235.s3.e0" e2="DDI-PubMed.25910235.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s3.e0" e2="DDI-PubMed.25910235.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25910235.s3.e2" e2="DDI-PubMed.25910235.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s3.e2" e2="DDI-PubMed.25910235.s3.e1" /></sentence><sentence text=" Results were compared to those noted with healthy volunteers following the adminstration of a single oral dose of MD"><entity charOffset="115-117" id="DDI-PubMed.25910235.s4.e0" text="MD" /></sentence><sentence text=" Sample preparation was performed by liquid-liquid extraction using t-butyl methyl ether"><entity charOffset="68-88" id="DDI-PubMed.25910235.s5.e0" text="t-butyl methyl ether" /></sentence><sentence text=" HPLC separation was carried out using RP C18 column (4" /><sentence text="6mm×50mm, 5μm)" /><sentence text=" Isocratic elution was performed using methanol:0"><entity charOffset="39-47" id="DDI-PubMed.25910235.s8.e0" text="methanol" /></sentence><sentence text="2% formic acid (70:30, v/v) as the mobile phase, at a flow rate of 0"><entity charOffset="3-14" id="DDI-PubMed.25910235.s9.e0" text="formic acid" /></sentence><sentence text="7mL/min" /><sentence text=" Tandem mass spectrometric detection was employed at positive electrospray ionization in MRM mode for the determination of MD and DMD"><entity charOffset="123-133" id="DDI-PubMed.25910235.s11.e0" text="MD" /><entity charOffset="131-141" id="DDI-PubMed.25910235.s11.e1" text="MD" /><entity charOffset="130-140" id="DDI-PubMed.25910235.s11.e2" text="DMD" /><pair ddi="false" e1="DDI-PubMed.25910235.s11.e0" e2="DDI-PubMed.25910235.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25910235.s11.e0" e2="DDI-PubMed.25910235.s11.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s11.e0" e2="DDI-PubMed.25910235.s11.e1" /><pair ddi="false" e1="DDI-PubMed.25910235.s11.e2" e2="DDI-PubMed.25910235.s11.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s11.e2" e2="DDI-PubMed.25910235.s11.e1" /></sentence><sentence text=" Analysis was carried out within 1" /><sentence text="0min over a concentration range of 0" /><sentence text="50-40" /><sentence text="00ng/mL for the prodrug and its active metabolite" /><sentence text=" The assay was validated according to FDA guidelines for bioanalytical method validation and satisfactory results were obtained" /><sentence text=" The applicability of the assay for the determination of the pharmacokinetic parameters of MD and DMD and personalized therapy was demonstrated in healthy volunteers and ascitic patients"><entity charOffset="91-93" id="DDI-PubMed.25910235.s17.e0" text="MD" /><entity charOffset="99-101" id="DDI-PubMed.25910235.s17.e1" text="MD" /><entity charOffset="98-100" id="DDI-PubMed.25910235.s17.e2" text="DMD" /><pair ddi="false" e1="DDI-PubMed.25910235.s17.e0" e2="DDI-PubMed.25910235.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25910235.s17.e0" e2="DDI-PubMed.25910235.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s17.e0" e2="DDI-PubMed.25910235.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25910235.s17.e2" e2="DDI-PubMed.25910235.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25910235.s17.e2" e2="DDI-PubMed.25910235.s17.e1" /></sentence><sentence text=" Results revealed significant differences in pharmacokinetic parameters among the studied groups" /><sentence text=" Such differences were explained on the basis of the medical condition and co-adminstered medications exerting possible drug-drug interaction" /><sentence text=" Results confirmed the need for implementation of reliable analysis tools for therapeutic dose adjustment" /><sentence text=" " /></document>